Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes

NCT02236481 | Terminated Phase 4

• 1 other identifier: TRACK
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

The TRACK \[Treatment of Rheumatoid Arthritis and Comorbidities with Kineret (anakinra)\]-study: a randomized, open-label multicenter study assessing the efficacy of anakinra in lowering HbA1c (glycated hemoglobin) as well as changes in DAS28 in Rheumatoid Arthritis (R.A.) patients with type 2 diabetes (T2D) Authors: R. Giacomelli,(A,B) P. Cipriani (A) and P. Ruscitti (A) on behalf of the TRACK study-group; (A) University of L'Aquila, L'Aquila, Italy; Background: Interleukin-1 (IL-1) plays a pivotal role in R.A., joint erosion and cartilage destruction.(1) Anakinra (a recombinant form of the naturally occurring IL-1 receptor antagonist (IL-1Ra), which blocks the activity of both IL-1α and IL-1β) has shown in a number of RCTs (2-6) to be effective in the treatment of R.A., in monotherapy,(2,4) as well as associated to methotrexate (MTX).(3,5,6) IL-1β plays also an important role in the pathogenesis of T2D: Glucose has been shown to induce IL-1β hypersecretion through inflammasome activation, while IL-1β induces impairment of β-cell secretory function and β-cell apoptosis.(7) In prediabetic subjects, the expression of IL-1Ra is induced by IL-1β and reflects the body's response to counterbalance increased IL-1β activity.(7) Levels of IL-1Ra tend to rise up to 6 years before the diagnosis of T2D.(8,9) IL-1Ra has been successfully used as a marker for the risk of developing T2D in subjects with metabolic syndrome.(10) As a clinical proof of concept, IL-1 inhibition with anakinra in patients with T2D has shown to improve the secretorial function of beta-cells as well as to lower the ratio of proinsulin/insulin and glycated hemoglobin/hemoglobin significantly, favoring glycemic control and possibly reducing the severity and prevalence of the associated complications of this disease.(11) Summarizing, IL-1 inhibition with anakinra has a clinical impact on R.A. as well as T2D. As from 6-10% of Italian R.A. patients have also T2D, this trial aims at investigating the impact of IL-1 inhibition on both diseases. Very recent data also show that T2D is a predictor of response to anakinra-treatment in R.A. patients,(12) which furthermore justifies the use of anakinra in this subset of R.A. patients. Objectives: \[Primary\] To evaluate the change in HbA1c between baseline, 3 months, 6 months, 1 year and at last follow up of 2 years from the beginning; \[Secondary\] To evaluate the efficacy on controlling signs \& symptoms of R.A., assessing the remission rate at 3 months, 6 months, 1 year and at follow up (2 years), using the evaluation scale of disease activity on 28 joints, DAS28 and SDAI improvements from baseline conditions over time points, according to EULAR response criteria. Methods: 200 patients in 28 Italian centers with active R.A. refractory to treatment with methotrexate and T2D will be enrolled and randomized to receive either 100mg of anakinra once daily by subcutaneous injection or any anti-TNF-alfa drug treatment. \[84 subjects will be required in each treatment arm to reach 90% power with an alpha error of 0.05 to detect a mean difference between the study arms of 0.25 percentage points of HbA1c . The assumed difference of HbA1c is rather conservative when compared to previously published changes in T2D patients (11).\] Anti-diabetic treatment is required to be unchanged for at least one month prior to enrolment. Patients will be invited to maintain dietary habits and lifestyle during the study period. Further details can be viewed on the trials website after subscription.(13) References: (1) Arend \& Dayer, Adv. Imm. 1993; 54: 167-227. (2) Bresnihan, Arthritis Rheum. 1998; 41: 2196-2204. (3) Cohen, Arthritis Rheum. 2002; 46: 614-624. (4) Nuki, Arthritis. Rheum. 2002; 46: 2838-2846. (5) Cohen, ARD 2004; 63: 1062-1068. (6) Cohen, Rheumatology 2004; 43: 704-711. (7) Donath, Nat. Rev. Immunol. 2011; 11: 98-107. (8) Herder, Diabetes Care 2009; 32: 421-423. (9) Carstensen, Diabetes 2010; 59: 1222-1227. (10) Luotola, J. Intern. Med. 2011; 269: 322-332. (11) Larsen, NEJM 2007; 356: 1517-1526. (12) Missler-Karger, EULAR 2013, Abs. FRI0219. (13) http://www.anakinra-ra-diabetes.org/ Disclosure: This trial is receiving support from Swedish Orphan Biovitrum AB according to the Italian law decree 17 December 2004. (B) speaker fees

Conditions

Diabetes Mellitus, Type 2; Arthritis, Rheumatoid

Outcome Measures

Primary Outcomes (1)

• Glycated Hemoglobin

  up to 24th months of treatment

Secondary Outcomes (7)

• Percentage of patients in remission ( EULAR Criteria )

  baseline , after 3 months, 6 months , 12 months and 24 months of treatment

• Percentage of patients improved ( EULAR criteria)

  baseline , after 3 months, 6 months , 12 months and 24 months of treatment

• Count of tender joints (66 joints)

  baseline , after 3 months, 6 months , 12 months and 24 months of treatment

• Count of swollen joints (68 joints)

  baseline , after 3 months, 6 months , 12 months and 24 months of treatment

• Administration at Health Assessment Questionnaire ( HAQ)

  baseline , after 3 months, 6 months , 12 months and 24 months of treatment

Study Arms (2)

Anakinra

EXPERIMENTAL

100 mg of anakinra once daily by subcutaneous injection for 24 months

Drug: Anakinra

TNF alpha inhibitors

ACTIVE COMPARATOR

treatment with TNF-alpha inhibitors according to the relative summary of product charateristics

Drug: TNF alpha inhibitors

Interventions

Anakinra DRUG

Also known as: Kineret

Anakinra

TNF alpha inhibitors DRUG

TNF alpha inhibitors

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• male and female patients aged ≥ 18 years;
• previous diagnosis of RA with criteria of the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR);
• Diagnosis of Diabetes Mellitus type II according to the American Diabetes Association (ADA) criteria since at least 6 months;
• Patients with an inadequate response to previous treatment with methotrexate (determined on the basis of the evaluation of the physician);
• BMI \<35
• Glycated hemoglobin \> 7% \<10%
• Minimum score Disease Activity Score-28 (DAS 28) \> 3.2
• For patients previously treated with a biologic drug, wash out of the treatment for at least 1 month prior to enrollment;
• For patients in treatment with hypoglycemic drugs at enrollment, no change of the hypoglycemic treatment in terms of type of drug and dosage, for a period of at least 3 months before enrolment
• For patients in therapy with other drugs at baseline, no change in terms of drug administered and the dosage regimen for a period of at least 1 month prior to enrollment;
• Absence of signs and symptoms related to ischemic heart disease
• Signature of written Informed Consent Form.

You may not qualify if:

• DM2 diagnosed since more than 10 years;
• Ongoing Acute infection or chronic infection, which has one or more of following:
• Increased levels of C-reactive protein \> 30 mg / L
• fever
• Ongoing treatment with antibiotics ;
• Chronic granulomatous infections (ie. tuberculosis diagnosed by radiography or by laboratory tests)
• History of recurrent infections or presence of diseases that induce to infections;
• C-peptide values \<0.5 ng / mL ( 0.1665 nmol / L)
• presence of neutropenia ( WBC \< 2000/mm3 ) or anemia (hemoglobin \< 11g/dL for man and 10g/dl for the woman) ;
• presence of one or more contraindication indicate in SmPC of study drug (anakinra);
• presence of one or more contraindication indicate in SmPC of control drug (inhibitors of TNF -alpha ; ATC L04AB);
• presence of one or more contraindications to treatment with methotrexate ;
• previous ischemic attack or myocardial infarction;
• heart failure NYHA class III or IV;
• hepatic or progressive liver disease ( values of ALAT / ASAT increased by at least two -fold compared to normal limits );

Sponsors & Collaborators

• Prof. Roberto Giacomelli: lead

Study Sites (1)

L'Aquila University

L’Aquila, 67100, Italy

Location

Related Publications (1)

• Ruscitti P, Masedu F, Alvaro S, Airo P, Battafarano N, Cantarini L, Cantatore FP, Carlino G, D'Abrosca V, Frassi M, Frediani B, Iacono D, Liakouli V, Maggio R, Mule R, Pantano I, Prevete I, Sinigaglia L, Valenti M, Viapiana O, Cipriani P, Giacomelli R. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 2019 Sep 12;16(9):e1002901. doi: 10.1371/journal.pmed.1002901. eCollection 2019 Sep.

  PMID: 31513665 DERIVED

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Arthritis, Rheumatoid

Interventions

Interleukin 1 Receptor Antagonist Protein

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Study Officials

• Roberto Giacomelli, Professor

  University of L'Aquila

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Full Professor of Rheumatology

Study Record Dates

• First Submitted: September 8, 2014
• First Posted: September 10, 2014
• Study Start: July 1, 2013
• Primary Completion: December 1, 2017
• Study Completion: December 1, 2017
• Last Updated: December 14, 2018

Record last verified: 2018-12

Locations

IT (1)